During SARS-Cov-2 pandemic, disinfectants producers and users started to wonder if a formulation can be effective against SARS-Cov2 specifically. The same trend has been observed in 2009, after a novel influenza A (H1N1) virus emerged in the US and quickly spread all over the world.
The US Environmental Protection Agency (EPA) has provided the possibility to enable test and register a previously EPA-registered disinfectants against emerging viral pathogens, not identified on the product label. >Check here
In response to market requests and Clients’ necessity, our virus testing laboratory is able to set-up and develop propagation of specific viruses and customized methods, for specific claim.
In such cases, firstly, a literature review on the best propagation method of the virus is performed. Meanwhile virus and host cell line are purchased from certified supplier.
Then, the R&D activity aims to achieve a good propagation of the cell line, determining the optimal splitting ratio and the optimal incubation conditions (appropriate culture medium and incubation time and temperature).
Once the cell line is effectively growing, the virus infection can be performed. Usually this phase includes screening of different M.O.Is. (multiplicity of infection). So different ratios of viral particles-cells are evaluate, performing viral titration at multiple incubation times (after 24 hour, 48 hours, etc…).
Once the higher viral titer has been obtained, based on the specific test method and requirements, a further concentration of the viral titer could be evaluated.
Generally, for this scope, a ultracentrifuge is used: different ultracentrifugation speeds and times could be evaluated in order to get the optimal yield in terms of viral titer.
This approach is adopted in order to increase our viral library, both in response to direct request from Customers willing to add specific product claim, both for viral clearance studies, that requires specific model viruses to be included and challenged in the validation process.
Our virus laboratory testing can manipulate and propagate up to Biosafety Level 2 viruses and is authorized for MGMO.
